Pfizer/Hospira Epogen Biosimilar Rejected; Relief For Amgen

Pfizer Inc. sneaked the news into its quarterly earnings call on Oct. 27 that its newly acquired subsidiary Hospira Inc. had received a complete response letter earlier this month from the FDA for its epoetin alfa biosimilar – a product Amgen Inc. has been working desperately through the US court system to keep off the market for a little while longer.